Legend Biotech Corp (LEGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.39B
Last updated: Nov 17, 2026 at 11:06 AM ET
Legend Biotech Corp (LEGN) Stock Forecast
Analysts expect Legend Biotech (LEGN) to earn -$0.01 per share in the fiscal year ending Dec 31, 2026, on revenue of $1.43B. Of 13 analysts, 8 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Buy. For the fiscal year ending Dec 31, 2027, the EPS consensus is $0.64.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 62% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 38.5% |
| Buy | 3 | 23.1% |
| Hold | 5 | 38.5% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 18.9%.
- Fiscal year ending Dec 31, 2026
- -$0.01
- EPS consensus, revenue $1.43B
- Fiscal year ending Dec 31, 2027
- $0.64
- EPS consensus, revenue $1.70B
- Fiscal year ending Dec 31, 2028
- $1.34
- EPS consensus, revenue $2.06B
- Next report
- Mar 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.01 | -$0.01 to -$0.01 | 1 | $1.43B | $1.42B to $1.44B | 7 |
| Dec 31, 2027 | $0.64 | $0.32 to $1.05 | 6 | $1.70B | $1.61B to $1.84B | 10 |
| Dec 31, 2028 | $1.34 | $1.02 to $1.66 | 2 | $2.06B | $2.01B to $2.11B | 10 |
Quarterly Estimates
The EPS consensus rises from $0.04 for the quarter ending Dec 31, 2026 to $0.13 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.04 | -$0.02 to $0.13 | 14 | $389.25M | $360.64M to $414.48M | 12 |
| Mar 31, 2027 | $0.13 | $0.13 to $0.13 | 1 | $401.90M | $380.00M to $443.19M | 3 |
Estimate Revisions
No EPS estimate for the 3 periods below was revised in the last 30 days.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 0 |
| Fiscal year ending Dec 31, 2027 | 0 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 0 |
EPS Trend
The EPS consensus for the fiscal year ending Dec 31, 2026 has held over the last 90 days.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | -$0.01 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.64 | $0.68 | $0.68 | $0.81 | $0.88 | -28.1% |
| Quarter ending Mar 31, 2027 | $0.13 | $0.13 | $0.13 | $0.13 | $0.22 | -40.9% |
Frequently Asked Questions About LEGN
What is the LEGN stock forecast?
Consensus analyst estimates put Legend Biotech's EPS at -$0.01 for the fiscal year ending Dec 31, 2026, on revenue of $1.43B. The consensus rating from 13 analysts is Buy.
How do analysts rate LEGN stock?
Of 13 analysts covering Legend Biotech, 5 rate it Strong Buy, 3 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from LEGN next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.01, with estimates from -$0.01 to -$0.01 from 1 analyst. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.64, with estimates from $0.32 to $1.05 from 6 analysts.
What revenue do analysts expect from Legend Biotech next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $1.43B, with estimates from $1.42B to $1.44B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $1.70B, with estimates from $1.61B to $1.84B.
How many analysts cover LEGN?
13 analysts rate Legend Biotech stock, and 1 analyst estimates its EPS for the fiscal year ending Dec 31, 2026.
LEGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors